Immunic Q3 EPS Lifted by Brookline Capital Markets

Immunic, Inc. (NASDAQ:IMUX) – Equities researchers at Brookline Capital Markets boosted their Q3 2026 earnings per share estimates for Immunic in a research report issued to clients and investors on Wednesday, August 12th. Brookline Capital Markets analyst F. Ahmed now forecasts that the company will earn ($0.84) per share for the quarter, up from their prior estimate of ($1.07). The consensus estimate for Immunic’s current full-year earnings is ($3.93) per share. Brookline Capital Markets also issued estimates for Immunic’s Q4 2026 earnings at ($1.16) EPS and FY2026 earnings at ($3.86) EPS.

Immunic (NASDAQ:IMUX) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.36.

Several other equities research analysts have also recently weighed in on IMUX. LADENBURG THALM/SH SH upgraded shares of Immunic to a “strong-buy” rating in a research report on Wednesday, July 29th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immunic in a research report on Friday, May 29th. Wall Street Zen raised shares of Immunic from a “sell” rating to a “hold” rating in a research note on Saturday. Wolfe Research initiated coverage on shares of Immunic in a report on Friday, May 22nd. They issued an “outperform” rating on the stock. Finally, Lifesci Capital upgraded shares of Immunic to a “strong-buy” rating in a research report on Monday, May 4th. Three analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Immunic currently has an average rating of “Buy” and a consensus target price of $47.25.

Immunic Stock Performance

NASDAQ IMUX opened at $16.90 on Monday. The company has a market capitalization of $230.52 million, a P/E ratio of -3.86 and a beta of 1.41. Immunic has a one year low of $5.06 and a one year high of $17.17. The stock has a 50 day moving average price of $14.63 and a 200-day moving average price of $12.24.

Hedge Funds Weigh In On Immunic

Several large investors have recently modified their holdings of the stock. CTC Alternative Strategies Ltd. bought a new stake in Immunic in the first quarter worth $27,000. ADAR1 Capital Management LLC purchased a new position in Immunic during the first quarter worth $33,000. Qube Research & Technologies Ltd bought a new position in Immunic during the third quarter valued at $29,000. Focus Partners Wealth increased its position in Immunic by 1.5% during the third quarter. Focus Partners Wealth now owns 2,581,587 shares of the company’s stock valued at $2,276,000 after acquiring an additional 39,063 shares during the last quarter. Finally, Two Sigma Investments LP purchased a new stake in shares of Immunic in the third quarter valued at $52,000. Institutional investors own 51.82% of the company’s stock.

Immunic Company Profile

Immunic, Inc is a clinical-stage biopharmaceutical company focused on developing novel oral therapies to treat chronic inflammatory and autoimmune diseases as well as certain cancers. The company’s research strategy centers on small-molecule immunology, aiming to offer targeted treatments with improved safety and tolerability profiles. By modulating key signaling pathways within the immune system, Immunic seeks to address underlying disease mechanisms and achieve durable therapeutic benefits for patients.

Immunic’s lead product candidate, vidofludimus calcium (IMU-838), is an oral selective dihydroorotate dehydrogenase (DHODH) inhibitor in Phase 2 clinical development for conditions including ulcerative colitis, Crohn’s disease and relapsing multiple sclerosis.